NVS: Novartis AG Stocks News on April 19, 2025

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

NVS

Zacks

2 days ago

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever

NVS

Motley Fool

2 days ago

2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever

Novartis scores NFL deal to tackle health outcomes

NVS

Pharma Voice

2 days ago

Novartis scores NFL deal to tackle health outcomes

NVS

MT Newswires

4 days ago

BNP Paribas Initiates Novartis at Outperform Rating, $116 Price Target

Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke

NVS

TipRanks

4 days ago

Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

NVS

Zacks

5 days ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Novartis (NVS) Surges 4.0%: Is This an Indication of Further Gains?

NVS

Zacks

5 days ago

Novartis (NVS) Surges 4.0%: Is This an Indication of Further Gains?

NVS

Zacks

5 days ago

The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis

Novartis Commits $23 Billion to U.S. Expansion, Eyes Full Domestic Production of Key Medicines

NVS

GuruFocus.com

7 days ago

Novartis Commits $23 Billion to U.S. Expansion, Eyes Full Domestic Production of Key Medicines

NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat

NVS

Zacks

8 days ago

NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat

Novartis commits $23bn to US manufacturing amid tariff threats

NVS

Pharmaceutical Technology

8 days ago

Novartis commits $23bn to US manufacturing amid tariff threats

Pharma Stock Roundup: EU Nod to Expanded Use of ABBV, AZN Drugs & More

NVS

Zacks

8 days ago

Pharma Stock Roundup: EU Nod to Expanded Use of ABBV, AZN Drugs & More

Novartis Stock Rises After Swiss Drugmaker Promises to Boost U.S. Manufacturing

NVS

The Wall Street Journal

8 days ago

Novartis Stock Rises After Swiss Drugmaker Promises to Boost U.S. Manufacturing

NVS

MT Newswires

8 days ago

Sector Update: Health Care Stocks Mixed Premarket Friday

NVS

MT Newswires

8 days ago

Sector Update: Health Care

This Pharma Giant Will Invest $23 Billion in the U.S. It’s a Sign Trump’s Tariffs Are Working.

NVS

Barrons.com

8 days ago

This Pharma Giant Will Invest $23 Billion in the U.S. It’s a Sign Trump’s Tariffs Are Working.

Stocks to Watch Friday: JPMorgan, Wells Fargo, BlackRock, Novartis

NVS

The Wall Street Journal

8 days ago

Stocks to Watch Friday: JPMorgan, Wells Fargo, BlackRock, Novartis

Novartis Plans $23B Investment in US Facilities as Trump Threatens Pharma Tariffs

NVS

Investopedia

8 days ago

Novartis Plans $23B Investment in US Facilities as Trump Threatens Pharma Tariffs

Swiss Drugmaker Novartis Promises to Boost U.S. Manufacturing Amid Tariff Threats

NVS

The Wall Street Journal

8 days ago

Swiss Drugmaker Novartis Promises to Boost U.S. Manufacturing Amid Tariff Threats

Novartis to spend $23B to expand in the US

NVS

Yahoo Finance Video

8 days ago

Novartis to spend $23B to expand in the US

NVS

MT Newswires

8 days ago

Sector Update: Health Care Stocks Retreat Late Afternoon

Novo Nordisk, AbbVie, Other Stocks Tumble After Trump Threatens Pharma Tariffs

NVS

The Wall Street Journal

10 days ago

Novo Nordisk, AbbVie, Other Stocks Tumble After Trump Threatens Pharma Tariffs

NVS

Argus Research

12 days ago

Weekly Stock List

NVS

Argus Research

12 days ago

Market Digest: NVS

NVS

Argus Research

12 days ago

Analyst Report: Novartis AG

This Type of Cholesterol Is a Risk Factor for Heart Disease. Emerging Drugs from Lilly and Amgen Could Treat It.

NVS

Barrons.com

12 days ago

This Type of Cholesterol Is a Risk Factor for Heart Disease. Emerging Drugs from Lilly and Amgen Could Treat It.

Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure

NVS

Zacks

15 days ago

Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure

Trial monitors recommend Elevidys studies continue; Novartis kidney drug approved

NVS

BioPharma Dive

15 days ago

Trial monitors recommend Elevidys studies continue; Novartis kidney drug approved

Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year

NVS

Benzinga

16 days ago

Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year

FDA Grants Accelerated Approval to NVS Kidney Disease Drug

NVS

Zacks

16 days ago

FDA Grants Accelerated Approval to NVS Kidney Disease Drug

NVS

MT Newswires

16 days ago

Sector Update: Health Care Stocks Lean Lower Premarket Thursday

NVS

MT Newswires

16 days ago

Novartis Gets FDA Accelerated Approval for Vanrafia

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

NVS

PR Newswire

16 days ago

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Big Pharma Avoids Worst-Case Tariff Scenario

NVS

The Wall Street Journal

16 days ago

Big Pharma Avoids Worst-Case Tariff Scenario

NVS

Zacks

17 days ago

Novartis (NVS) Could Be a Great Choice

APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag

NVS

Zacks

17 days ago

APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag

Leqembi’s EU review drags on; Sanofi gets a new development head

NVS

BioPharma Dive

17 days ago

Leqembi’s EU review drags on; Sanofi gets a new development head

Isomorphic raises $600M on big ambitions for AI drugmaking tech

NVS

BioPharma Dive

19 days ago

Isomorphic raises $600M on big ambitions for AI drugmaking tech

JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer

NVS

Zacks

19 days ago

JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer

Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis

NVS

GlobeNewswire

19 days ago

Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis

NVS

MT Newswires

22 days ago

Novartis Gets FDA Approval for Expanded Pluvicto Indication

FDA broadens use of Novartis’ radiopharma drug Pluvicto

NVS

BioPharma Dive

22 days ago

FDA broadens use of Novartis’ radiopharma drug Pluvicto

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

NVS

GlobeNewswire

22 days ago

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

Here's Why Novartis (NVS) is a Strong Value Stock

NVS

Zacks

22 days ago

Here's Why Novartis (NVS) is a Strong Value Stock

NVS

Morningstar Research

22 days ago

Analyst Report: Novartis AG

5 Large Drug Stocks to Watch as Industry Recovers

NVS

Zacks

25 days ago

5 Large Drug Stocks to Watch as Industry Recovers

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

NVS

GlobeNewswire

25 days ago

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

Tempero secures $70m to advance addiction treatment candidate

NVS

Pharmaceutical Technology

a month ago

Tempero secures $70m to advance addiction treatment candidate

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

NVS

Zacks

a month ago

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains

NVS

Zacks

a month ago

Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains

Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli

NVS

TipRanks

a month ago

Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli

FDA Approves Novartis Drug for Rare Kidney Disease Treatment

NVS

Zacks

a month ago

FDA Approves Novartis Drug for Rare Kidney Disease Treatment

Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy

NVS

Zacks

a month ago

Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy

Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

NVS

Zacks

a month ago

Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease

NVS

Benzinga

a month ago

FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease

AstraZeneca deepens China investment; Editas loses CFO to Dyne

NVS

BioPharma Dive

a month ago

AstraZeneca deepens China investment; Editas loses CFO to Dyne

NVS

MT Newswires

a month ago

Novartis Gets FDA Clearance for First Approved Treatment For Rare Kidney Disease

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)

NVS

PR Newswire

a month ago

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)

Novartis Reports Updated Positive Data From Phase III SMA Program

NVS

Zacks

a month ago

Novartis Reports Updated Positive Data From Phase III SMA Program

Novartis builds case for new SMA gene therapy

NVS

BioPharma Dive

a month ago

Novartis builds case for new SMA gene therapy

Novartis reports Phase III efficacy and safety outcomes of SMA treatment

NVS

Clinical Trials Arena

a month ago

Novartis reports Phase III efficacy and safety outcomes of SMA treatment

Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades

NVS

Pharma Voice

a month ago

Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades

Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy

NVS

Benzinga

a month ago

Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy

New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA

NVS

GlobeNewswire

a month ago

New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA

Are You Looking for a High-Growth Dividend Stock?

NVS

Zacks

a month ago

Are You Looking for a High-Growth Dividend Stock?

NVS

MT Newswires

a month ago

Update: Market Chatter: Novartis Tracking US Reciprocal Tariff Policy 'Very Carefully'

NVS

MT Newswires

a month ago

Sector Update: Health Care Stocks Decline Premarket Monday

NVS

MT Newswires

a month ago

Market Chatter: Novartis Tracking US Reciprocal Tariff Policy 'Very Carefully'

Novartis is watching US reciprocal tariff policy 'very carefully', CEO says

NVS

Reuters

a month ago

Novartis is watching US reciprocal tariff policy 'very carefully', CEO says

Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?

NVS

Zacks

a month ago

Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

NVS

Zacks

a month ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Why Novartis (NVS) is a Top Value Stock for the Long-Term

NVS

Zacks

a month ago

Why Novartis (NVS) is a Top Value Stock for the Long-Term

NVS

Thomson Reuters StreetEvents

a month ago

Q4 2024 Legend Biotech Corp Earnings Call

Molecular Partners AG (MLLCF) (FY 2024) Earnings Call Highlights: Strategic Shifts and ...

NVS

GuruFocus.com

a month ago

Molecular Partners AG (MLLCF) (FY 2024) Earnings Call Highlights: Strategic Shifts and ...

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting

NVS

GlobeNewswire

a month ago

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting

3 Top Cancer Biotechs to Keep An Eye On in 2025

NVS

Zacks

a month ago

3 Top Cancer Biotechs to Keep An Eye On in 2025

ITM targets US approval for radiopharmaceutical after Phase III readout

NVS

Pharmaceutical Technology

a month ago

ITM targets US approval for radiopharmaceutical after Phase III readout

Novartis AG (NVS): Among the Best Undervalued Stocks to Invest In Now

NVS

Insider Monkey

a month ago

Novartis AG (NVS): Among the Best Undervalued Stocks to Invest In Now

Novartis Near Buy Point; Earns Near-Best Overall Rating

NVS

Investor's Business Daily

a month ago

Novartis Near Buy Point; Earns Near-Best Overall Rating

Novartis Earnings Surprised The Street; Still Going Strong

NVS

Investor's Business Daily

a month ago

Novartis Earnings Surprised The Street; Still Going Strong

NVS

MT Newswires

2 months ago

DA Davidson Downgrades Novartis to Neutral From Buy, Price Target is $120

Novartis Gets CHMP Opinion for Label Expansion of Fabhalta

NVS

Zacks

2 months ago

Novartis Gets CHMP Opinion for Label Expansion of Fabhalta

3 Dividend Stocks That Are No-Brainer Buys Right Now

NVS

Motley Fool

2 months ago

3 Dividend Stocks That Are No-Brainer Buys Right Now

NVS

Thomson Reuters StreetEvents

2 months ago

Q4 2024 PTC Therapeutics Inc Earnings Call

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

NVS

GlobeNewswire

2 months ago

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)

NVS

GlobeNewswire

2 months ago

Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)

PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...

NVS

GuruFocus.com

2 months ago

PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...

NVS

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Schrodinger Inc Earnings Call

Schrodinger Inc (SDGR) Q4 2024 Earnings Call Highlights: Strong Software Growth Amidst Revenue ...

NVS

GuruFocus.com

2 months ago

Schrodinger Inc (SDGR) Q4 2024 Earnings Call Highlights: Strong Software Growth Amidst Revenue ...

NVS

MT Newswires

2 months ago

Sector Update: Health Care Stocks Slip in Afternoon Trading

Court Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program

NVS

Benzinga

2 months ago

Court Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program

NVS

MT Newswires

2 months ago

Update: Novartis Stockholder Sandoz to Reportedly Sell 26.5 Million Shares

NVS

MT Newswires

2 months ago

Novartis Stockholder Sandoz to Reportedly Sell 26.5 Million Shares

Sandoz family to get $2.9 billion from offloading part of its Novartis stake

NVS

Reuters

2 months ago

Sandoz family to get $2.9 billion from offloading part of its Novartis stake

Sandoz Family Pares Novartis Stake With $2.9 Billion Sale

NVS

Bloomberg

2 months ago

Sandoz Family Pares Novartis Stake With $2.9 Billion Sale

NVS

MT Newswires

2 months ago

Sector Update: Health Care Stocks Higher Late Afternoon

NVS

MT Newswires

2 months ago

Sector Update: Health Care

NVS

MT Newswires

2 months ago

Update: Market Chatter: Emasan Offering to Sell 1.2% Stake in Novartis

NVS

MT Newswires

2 months ago

Market Chatter: Emasan Offering to Sell 1.2% Stake in Novartis

Here's Why Novartis (NVS) is a Strong Momentum Stock

NVS

Zacks

2 months ago

Latest Novartis AG (NVS) News on April 19, 2025

Share on Social Networks: